BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahonen J, Olkkola KT, Salmenperä M, Hynynen M, Neuvonen PJ. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology. 1996;85:1246-1252. [PMID: 8968170 DOI: 10.1097/00000542-199612000-00004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Hamaoka N, Oda Y, Hase I, Asada A. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies. British Journal of Anaesthesia 2001;86:540-4. [DOI: 10.1093/bja/86.4.540] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
2 Saari TI, Uusi-Oukari M, Ahonen J, Olkkola KT. Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. Pharmacol Rev 2011;63:243-67. [PMID: 21245208 DOI: 10.1124/pr.110.002717] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
3 Cheng JW, Frishman WH, Aronow WS. Updates on cytochrome P450-mediated cardiovascular drug interactions. Am J Ther 2009;16:155-63. [PMID: 19114873 DOI: 10.1097/MJT.0b013e31813e63be] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
4 Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44:279-304. [PMID: 15762770 DOI: 10.2165/00003088-200544030-00005] [Cited by in Crossref: 315] [Cited by in F6Publishing: 279] [Article Influence: 19.7] [Reference Citation Analysis]
5 Pinto AG, Horlander J, Chalasani N, Hamman M, Asghar A, Kolwankar D, Hall SD. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol 2005;59:440-6. [PMID: 15801939 DOI: 10.1111/j.1365-2125.2005.02343.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
6 Masica AL, Azie NE, Brater DC, Hall SD, Jones DR. Intravenous diltiazem and CYP3A-mediated metabolism. Br J Clin Pharmacol 2000;50:273-6. [PMID: 10971313 DOI: 10.1046/j.1365-2125.2000.00249.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
7 Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003; 9(9): 1959-1962 [PMID: 12970884 DOI: 10.3748/wjg.v9.i9.1959] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
8 Weaver RJ. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 2001;31:499-538. [PMID: 11569524 DOI: 10.1080/00498250110060950] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
9 Weingarten TN, Taenzer AH, Elkassabany NM, Le Wendling L, Nin O, Kent ML. Safety in Acute Pain Medicine-Pharmacologic Considerations and the Impact of Systems-Based Gaps. Pain Med 2018;19:2296-315. [PMID: 29727003 DOI: 10.1093/pm/pny079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Cheng JW, Frishman WH, Aronow WS. Updates on cytochrome p450-mediated cardiovascular drug interactions. Dis Mon 2010;56:163-79. [PMID: 20189501 DOI: 10.1016/j.disamonth.2009.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
11 Short TG, Young Y. Toxicity of intravenous anaesthetics. Best Pract Res Clin Anaesthesiol 2003;17:77-89. [PMID: 12751550 DOI: 10.1053/bean.2002.0266] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
12 Sawada T, Sako K, Yoshihara K, Nakamura K, Yokohama S, Hayashi M. Timed‐release formulation to avoid drug–drug interaction between diltiazem and midazolam. Journal of Pharmaceutical Sciences 2003;92:790-7. [DOI: 10.1002/jps.10336] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
13 Dunn SP, Holmes DR Jr, Moliterno DJ. Drug-drug interactions in cardiovascular catheterizations and interventions. JACC Cardiovasc Interv 2012;5:1195-208. [PMID: 23257367 DOI: 10.1016/j.jcin.2012.10.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
14 Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin*. Clin Pharmacol Ther 1998;64:369-77. [DOI: 10.1016/s0009-9236(98)90067-4] [Cited by in Crossref: 124] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
15 Williams S, Wynn G, Cozza K, Sandson NB. Cardiovascular Medications. Psychosomatics 2007;48:537-47. [DOI: 10.1176/appi.psy.48.6.537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Ahonen J, Sahlman A, Yli-hankala A, Eriksson H, Nemlander A, Rämö J, Salmenperä M. No effect of cardiopulmonary bypass on hypnosis in patients anaesthetized with propofol and alfentanil. British Journal of Anaesthesia 2004;92:137-9. [DOI: 10.1093/bja/aeh021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ahonen J, Olkkola KT, Hynynen M, Seppälä T, Ikävalko H, Remmerie B, Salmenperä M. Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. Br J Anaesth 2000;85:533-40. [PMID: 11064610 DOI: 10.1093/bja/85.4.533] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
18 Ahonen J, Olkkola KT, Verkkala K, Heikkinen L, Järvinen A, Salmenperä M. A Comparison of Remifentanil and Alfentanil for Use with Propofol in Patients Undergoing Minimally Invasive Coronary Artery Bypass Surgery: . Anesthesia & Analgesia 2000;90:1269-74. [DOI: 10.1097/00000539-200006000-00003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
19 Moody DE. Drug Interactions with Benzodiazepines. In: Mozayani A, Raymon LP, editors. Handbook of Drug Interactions. Totowa: Humana Press; 2004. pp. 3-88. [DOI: 10.1007/978-1-59259-654-6_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Milde AS, Motsch J. [Drug interactions and the anesthesiologist]. Anaesthesist 2003;52:839-59. [PMID: 14575048 DOI: 10.1007/s00101-003-0563-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
21 Liston HL, Markowitz JS. Opioid Drug-Drug Interactions: A Review. Journal of Pharmacy Practice 1998;11:325-41. [DOI: 10.1177/089719009801100504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
22 Prielipp RC, Young CC. Current drugs for sedation of critically ill patients. Seminars in Anesthesia, Perioperative Medicine and Pain 2001;20:85-94. [DOI: 10.1053/sane.2001.23381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
23 Levin TT, Bakr MH, Nikolova T. Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction. Gen Hosp Psychiatry 2010;32:648.e9-648.e10. [PMID: 21112467 DOI: 10.1016/j.genhosppsych.2010.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
24 Zhou S, Chan E, Li X, Huang M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 2005;1:3-13. [PMID: 18360537 DOI: 10.2147/tcrm.] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
25 Moody DE. Drug Interactions with Benzodiazepines: Epidemiologic Correlates with Other CNS Depressants and In Vitro Correlates with Inhibitors and Inducers of Cytochrome P450 3A4. In: Mozayani A, Raymon L, editors. Handbook of Drug Interactions. Totowa: Humana Press; 2012. pp. 25-116. [DOI: 10.1007/978-1-61779-222-9_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SA Jr, Murray MJ, Peruzzi WT, Lumb PD; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-41. [PMID: 11902253 DOI: 10.1097/00003246-200201000-00020] [Cited by in Crossref: 1275] [Cited by in F6Publishing: 991] [Article Influence: 67.1] [Reference Citation Analysis]
27 Yu SKH, Tait G, Karkouti K, Wijeysundera D, Mccluskey S, Beattie WS. The Safety of Perioperative Esmolol: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Anesthesia & Analgesia 2011;112:267-81. [DOI: 10.1213/ane.0b013e3182025af7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]